Journal of Integrative Oncology

Research Institute in Healthcare Science, California, USA

Publications

• Mini Review   
  Editorial on Cancer Immunotherapy's Multidimensional Biomarker Landscape
  Author(s): Edward Takes*
  
  Late advances in the field of immuno-oncology have prompted a change in perspective in the norm of care for human tumors. A superior comprehension of resistant observation wherein inborn safe cells kill disease cells, combined with the disclosure of T-cell invulnerable designated spot inhibitors (ICIs), have essentially further developed endurance results and personal satisfaction for some patients. Immunizer barricade of resistant designated spots Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) and Programmed cell Death 1 (PD1)/PD1 ligand 1 (PD-L1) have been displayed to reestablish antitumor invulnerability in various growth types, for example, melanoma, renal cell carcinoma, non-little cell lung carcinoma and Hodgkin's lymphoma. Nonetheless, as more growth types exhibiting likely advantage to ICIs are noted, strong reactions are noticed exclusively in little subse.. Read More»
  DOI: 10.37421/2329-6771.2022.11.387

  Abstract HTML PDF